Most people skip the due diligence that matters. Legality varies by country. Sourcing quality varies by batch. Evidence strength varies by compound. This checklist covers all of it — in plain language.
Enter your email — we'll send a confirmation, then the PDF. No countdown timers. No upsell sequence. One email to confirm, one to deliver.
8 categories, 12 questions. Each one points to a real risk or knowledge gap that vendor-funded content routinely skips.
Legal status varies sharply by country and compound. GLP-1 is prescription-only; BPC-157 is a controlled substance in Australia. Checking your drug agency's scheduling list — not a vendor FAQ.
BPC-157 is banned by WADA under S0 (non-approved substances). National legality and anti-doping eligibility are independent — you can be legal and still face a ban.
Third-party Certificates of Analysis (CoA) from independent labs — not vendor claims. Batch-matched, not generic. For injectables, sterility documentation.
Relevant pre-protocol labs by compound. A baseline makes it possible to evaluate effects and catch problems early.
GLP-1 slows gastric emptying — this affects absorption timing of oral medications including warfarin, thyroid meds, and oral contraceptives.
The label means no regulatory body has reviewed it for human use — not that it's been tested and cleared. The gap in evidence matters for risk estimation.
What to look for: disclosed testing partners, batch-specific CoAs, no therapeutic claims. What to avoid: clinical testimonials and "guaranteed results."
Pre-defined stopping criteria: what symptoms or lab changes would cause you to stop immediately. A stopping protocol means you've thought about risk before you're inside it.
Independent, research-first content on GLP-1, BPC-157, and GHK-Cu. Every guide starts with the primary research — PubMed, clinical trial registries, peer-reviewed pharmacology — not vendor claims. No affiliate relationships, no sponsored content.